This document discusses the challenges of commercializing cellular therapies and how automation can help address those challenges. It outlines the innovation continuum from basic research to commercialization. Key challenges include meeting regulatory requirements, scaling production processes for higher volumes, and justifying the investment in automation. The document recommends taking a risk-driven design approach and developing cost models to help guide development priorities and investment scenarios. It emphasizes starting early with regulatory planning and positioning automation as enabling increased capacity and lower costs.